Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * DHILLON PUNIT 2. Issuer Name and Ticker or Trading Symbol Skye Bioscience, Inc. [SKYE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) 11250 EL CAMINO REAL, SUITE 100, C/O SKYE BIOSCIENCE, INC. 3. Date of Earliest Transaction (Month/Day/Year) 03/31/2026 (Street) SAN DIEGO, CA 92130 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.615(1)	03/31/2026		A		250,000		(2)	02/25/2035	Common Stock	250,000	(3)	250,000	D
Stock Option (Right to Buy)	$2.89	03/31/2026		D			250,000	(2)	02/25/2035	Common Stock	250,000	(3)	0	D
Stock Option (Right to Buy)	$0.615(1)	03/31/2026		A		36,000		(2)	08/07/2030	Common Stock	36,000	(3)	36,000	D
Stock Option (Right to Buy)	$11.25	03/31/2026		D			36,000	(2)	08/07/2030	Common Stock	36,000	(3)	0	D
Stock Option (Right to Buy)	$0.615(1)	03/31/2026		A		12,360		(2)	12/14/2031	Common Stock	12,360	(3)	12,360	D
Stock Option (Right to Buy)	$14.5	03/31/2026		D			12,360	(2)	12/14/2031	Common Stock	12,360	(3)	0	D
Stock Option (Right to Buy)	$0.615(1)	03/31/2026		A		650,000		(4)	10/27/2034	Common Stock	650,000	(3)	650,000	D
Stock Option (Right to Buy)	$5.15	03/31/2026		D			650,000	(4)	10/27/2034	Common Stock	650,000	(3)	0	D
Stock Option (Right to Buy)	$0.615(1)	03/31/2026		A		125,000		(5)	03/01/2034	Common Stock	125,000	(3)	125,000	D
Stock Option (Right to Buy)	$14.56	03/31/2026		D			125,000	(5)	03/01/2034	Common Stock	125,000	(3)	0	D
Stock Option (Right to Buy)	$0.615(1)	03/31/2026		A		9,013		(6)	11/06/2033	Common Stock	9,013	(3)	9,013	D
Stock Option (Right to Buy)	$3.5	03/31/2026		D			9,013	(6)	11/06/2033	Common Stock	9,013	(3)	0	D
Stock Option (Right to Buy)	$0.615(1)	03/31/2026		A		21,586		(7)	09/29/2033	Common Stock	21,586	(3)	21,586	D
Stock Option (Right to Buy)	$3.5	03/31/2026		D			21,586	(7)	09/29/2033	Common Stock	21,586	(3)	0	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
DHILLON PUNIT 11250 EL CAMINO REAL, SUITE 100 C/O SKYE BIOSCIENCE, INC. SAN DIEGO, CA 92130	X		Chief Executive Officer

Signatures

/s/ Punit S. Dhillon		04/02/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing.
(2)	The stock option is fully vested.
(3)	On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged.
(4)	The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 27, 2024. Upon a change of control of the Issuer, 100% of the stock option will become fully vested.
(5)	The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is March 1, 2024. Upon a change in control of the Issuer, 100% of the stock options will become fully vested.
(6)	The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested
(7)	The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.